Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord Medical CoROCO:6518 -0.65%71 EBITDA Margin % is 17.56% as of Dec. 2025, which is 6% above its 10-year median of 16.59. GuruFocus rates ROCO:6518 with a GF Score™ of 71/100 and a GF Value™ of NT$29.15 (Fairly Valued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Concord Medical Co ranks better than 71.53% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Concord Medical Co's EBITDA for the
six
months ended in Dec. 2025 was NT$90.5 Mil. Concord Medical Co's Revenue for the
six
months ended in Dec. 2025 was NT$515.5 Mil. Therefore, Concord Medical Co's EBITDA margin for the quarter that ended in Dec. 2025 was 17.56%.
Concord Medical Co (ROCO:6518) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Concord Medical Co EBITDA Margin % Related Terms
Concord Medical Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Concord Medical Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6518 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Concord Medical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Medical Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Concord Medical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Concord Medical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Medical Co (ROCO:6518) has a EBITDA Margin % of 17.56% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Concord Medical Co and its competitors. This is near median its historical median of 16.59. Over the past decade, Concord Medical Co's EBITDA Margin % has ranged from 12.10 to 19.94. According to the industry distribution chart, Concord Medical Co ranks #232 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 28.5%.
Is Concord Medical Co's EBITDA Margin % too high?
Concord Medical Co's current EBITDA Margin % of 17.56% is near median its 10-year median of 16.59. Over the past 10 years, this metric has ranged from a low of 12.10 to a high of 19.94. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. Concord Medical Co's value of 17.56% is 133.5% above this industry median. Based on the distribution chart, Concord Medical Co ranks #232 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Concord Medical Co has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Concord Medical Co's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Concord Medical Co ranks #232 out of 815 companies for EBITDA Margin %. This puts Concord Medical Co in the upper half of its industry. The industry median EBITDA Margin % is 7.52. Concord Medical Co's value of 17.56% is 133.5% above this benchmark. Historically, Concord Medical Co's own EBITDA Margin % has ranged from 12.10 to 19.94 over the past decade. While the company's 10-year median is 16.59 vs. the industry median of 7.52, Concord Medical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Medical Co's current EBITDA Margin % of 17.56% is 133.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Concord Medical Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Medical Co's current EBITDA Margin % is 17.56%, which is near median its own 10-year median of 16.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Concord Medical Co (ROCO:6518) is currently considered Fairly Valued. The stock's GF Value™ is NT$29.15, compared to a current price of NT$30.40 — trading 4.3% above its estimated fair value. The current EBITDA Margin % is 17.56%, which is near median its 10-year median of 16.59 and 133.5% above the Medical Devices & Instruments industry median of 7.52. Concord Medical Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Concord Medical Co (ROCO:6518), the current EBITDA Margin % is 17.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Medical Co (ROCO:6518) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Medical Co stock appears to be overvalued.
The current stock price of NT$30.40 is trading 4.3% above its estimated GF Value™ of NT$29.15.
GuruFocus considers Concord Medical Co to be Fairly Valued.
Key valuation signals for ROCO:6518:
EBITDA Margin %: 17.56% (near median its 10-year median of 16.59)
GF Value™: NT$29.15 vs. price of NT$30.40 (4.3% above fair value)
Industry Position: 133.5% above the Medical Devices & Instruments median (#232 of 815)
No single metric tells the full story. See the ROCO:6518 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Medical Co Ltd is a Taiwan based company involved in providing hospital management support services including medical equipment leasing, pharmaceuticals, and medical consumables integrated supply. . The company's main business items are medical equipment, pharmaceuticals Product trading business, leasing business and management consulting services.
71GF Score
Get the complete analysis for ROCO:6518
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6518 has been successfully added to your 
